Arcutis Biotherapeutics, Inc.ARQTEarnings & Financial Report
Arcutis Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies for immune-mediated dermatological diseases. Its core product portfolio targets conditions including psoriasis, atopic dermatitis, and alopecia areata, primarily serving patients and healthcare providers across the United States, addressing unmet needs in the dermatology care segment.
ARQT Q2 FY2026 Key Financial Metrics
Revenue
$129.5M
Gross Profit
$117.8M
Operating Profit
$18.4M
Net Profit
$17.4M
Gross Margin
91.0%
Operating Margin
14.2%
Net Margin
13.4%
YoY Growth
81.5%
EPS
$0.13
Arcutis Biotherapeutics, Inc. Q2 FY2026 Financial Summary
Arcutis Biotherapeutics, Inc. reported revenue of $129.5M (up 81.5% YoY) for Q2 FY2026, with a net profit of $17.4M (13.4% margin). Cost of goods sold was $11.7M, operating expenses totaled $99.4M.
Key Financial Metrics
| Total Revenue | $129.5M |
|---|---|
| Net Profit | $17.4M |
| Gross Margin | 91.0% |
| Operating Margin | 14.2% |
| Report Period | Q2 FY2026 |
Arcutis Biotherapeutics, Inc. Annual Revenue by Year
Arcutis Biotherapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $376.1M).
Arcutis Biotherapeutics, Inc. Quarterly Revenue & Net Profit History
Arcutis Biotherapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2026 | $129.5M | +81.5% | $17.4M | 13.4% |
| Q1 FY2026 | $105.4M | +60.1% | $-11.3M | -10.7% |
| Q4 FY2025 | $129.5M | +81.5% | $17.4M | 13.4% |
| Q3 FY2025 | $99.2M | +121.7% | $7.4M | 7.5% |
| Q2 FY2025 | $81.5M | +164.1% | $-15.9M | -19.5% |
| Q1 FY2025 | $65.8M | +32.8% | $-25.1M | -38.1% |
| Q4 FY2024 | $71.4M | +427.6% | $-10.8M | -15.1% |
| Q3 FY2024 | $44.8M | +17.4% | $-41.5M | -92.8% |
Income Statement
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $44.8M | $71.4M | $65.8M | $81.5M | $99.2M | $129.5M | $105.4M | $129.5M |
| YoY Growth | 17.4% | 427.6% | 32.8% | 164.1% | 121.7% | 81.5% | 60.1% | 81.5% |
Balance Sheet
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $437.4M | $348.9M | $344.1M | $352.4M | $371.0M | $433.0M | $460.0M | $433.0M |
| Liabilities | $280.7M | $191.3M | $201.4M | $213.5M | $212.9M | $243.5M | $270.4M | $243.5M |
| Equity | $156.6M | $157.5M | $142.7M | $139.0M | $158.1M | $189.5M | $189.6M | $189.5M |
Cash Flow
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|
| Operating CF | $-34.7M | $-748000 | $-30.4M | $324000 | $-1.8M | $26.2M |